Recent Updates
Recently added Catalysts

Inaxaplin

Phase 2

Proteinuric Kidney Disease | Small molecule | Nephrology |Vertex Pharmaceuticals Incorporated|Last Updated: Aug 20, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment42

FDA Designations

No designations recorded

Clinical trial landscape

Inaxaplin · 1 trial · 1 indication

Phase 2 1
NCT06794996Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesProteinuric Kidney Disease
COMPLETED42 Analytics
PHASE2COMPLETED
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
Proteinuric Kidney Disease
NCT0679499642
Unlock trial analytics

Study Endpoints

Primary Endpoints

Percent Change in Urine Albumin-Creatinine Ratio (UACR)
Baseline and At Week 13

Secondary Endpoints

Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
From Baseline Up To Week 17
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
IXP (Inaxaplin)EXPERIMENTALParticipants with proteinuric APOL1-mediated kidney disease (AMKD) with or without the comorbidity of Type 2 diabetes mellitus (T2DM) will receive a single dose of IXP once daily, for 13 weeks.

Interventions

NameTypeDescription
InaxaplinDRUGTablets for Oral Administration.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 67 Years
SexALL
Healthy VolunteersNo
Study Sites35

Key Inclusion Criteria: * Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay * Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening Key Exc...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

HIGHAug 20, 2026NCT06794996Status: ACTIVE_NOT_RECRUITING → COMPLETED
HIGHAug 20, 2026NCT06794996Status: ACTIVE_NOT_RECRUITING → COMPLETED

Frequently asked questions about Inaxaplin

What is Inaxaplin used for?

Inaxaplin is an investigational small molecule being developed for the treatment of proteinuric kidney disease, a condition characterized by excess protein in the urine. It is being studied in patients with proteinuric APOL1 mediated kidney disease, with or without comorbidities. The drug is currently in Phase 2 clinical development.

Who makes Inaxaplin?

Inaxaplin is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. Vertex is conducting clinical research to evaluate the safety and efficacy of Inaxaplin in patients with proteinuric kidney disease.

What phase is Inaxaplin in?

Inaxaplin is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for the treatment of proteinuric kidney disease, specifically in patients with APOL1 mediated kidney disease.

What clinical trials is Inaxaplin in?

Inaxaplin has been studied in one clinical trial with the identifier NCT06794996. This Phase 2 trial, titled 'Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities,' was completed in the United States. The trial enrolled 42 adult participants of all sexes and was uncontrolled, meaning there was no comparator group.

Is Inaxaplin the same as any other drug?

Inaxaplin is the sole name provided for this investigational drug. There are no alternative names listed for Inaxaplin in the available information. It is a small molecule being developed by Vertex Pharmaceuticals for the treatment of proteinuric kidney disease.